Artificial intelligence based treatment planning of radiotherapy for locally advanced breast cancer

Background and purpose: Treatment planning of radiotherapy for locally advanced breast cancer patients can be a time consuming process. Artificial intelligence based treatment planning could be used as a tool to speed up this process and maintain plan quality consistency. The purpose of this study w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dennis van de Sande, Marjan Sharabiani, Hanneke Bluemink, Esther Kneepkens, Nienke Bakx, Els Hagelaar, Maurice van der Sangen, Jacqueline Theuws, Coen Hurkmans
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/07caacea83cd4701b752341561a171a3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Background and purpose: Treatment planning of radiotherapy for locally advanced breast cancer patients can be a time consuming process. Artificial intelligence based treatment planning could be used as a tool to speed up this process and maintain plan quality consistency. The purpose of this study was to create treatment plans for locally advanced breast cancer patients using a Convolutional Neural Network (CNN). Materials and methods: Data of 60 patients treated for left-sided breast cancer was used with a training, validation and test split of 36/12/12, respectively. The in-house built CNN model was a hierarchically densely connected U-net (HD U-net). The inputs for the HD U-net were 2D distance maps of the relevant regions of interest. Dose predictions, generated by the HD U-net, were used for a mimicking algorithm in order to create clinically deliverable plans. Results: Dose predictions were generated by the HD U-net and mimicked using a commercial treatment planning system. The predicted plans fulfilling all clinical goals while showing small (≤0.5 Gy) statistically significant differences (p < 0.05) in the doses compared to the manual plans. The mimicked plans show statistically significant differences in the average doses for the heart and lung of ≤0.5 Gy and a reduced D2% of all PTVs. In total, ten of the twelve mimicked plans were clinically acceptable. Conclusions: We created a CNN model which can generate clinically acceptable plans for left-sided locally advanced breast cancer patients. This model shows great potential to speed up the treatment planning process while maintaining consistent plan quality.